NCCN Pharmacy Updates: Novel Agents for the Treatment of Relapsed/Refractory Multiple Myeloma
Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma. Pharmacists should be aware of the new data and recommendations surrounding these novel agents and how they relate to improvements in patient survival and quality of life.
  • Multiple Myeloma
  • Live Webinar
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date June 9, 2021